MIB FACTOR AGENTS OSTEOSARCOMA CONFERENCE
February 27 - 29, 2020 PHOENIX ARIZONA
THE SCOTTSDALE RESORT AT MCCORMICK RANCH
#FACTOR2020 #BELIEVEINBETTER
MIB AGENTS MISSION STATEMENT

MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer.

**MIB MISSIONS**

An MIB Mission is for a child with osteosarcoma who has transitioned to hospice care. Together with our Mission Commander, the OsteoWarrior will develop a personalized mission. A Mission can be an item of comfort or entertainment or an experience to share with family.

**MIB AMBASSADOR AGENTS**

MIB Ambassadors are trained Agents who offer support, love and hope to each other; Warrior-to-Warrior, Father-to-Father, Mother-to-Mother, Sibling-to-Sibling. Our journeys will be different, but there is a connection between those who have walked the osteosarcoma path that is strong and comforting. Ambassadors support patients and families in active treatment through hospital visits, phone, email and text communication, gaming, MIB Swag Bags and Caregiver Go Bags.

**GAMER AGENTS**

Video Gaming is a wonderful way to have fun while in treatment. MIB Lead Gamer Agents are trained Ambassador Agents who game with survivors, warriors and current patients of osteosarcoma. OsteoWarriors who are out of treatment are paired with an OsteoWarrior who is in treatment. They battle together on the game and system [Xbox, PS] of their choice.

**PRAYER AGENTS**

Prayers, intentions and positive thoughts are so uplifting to many OsteoWarriors and their families. Prayer Agents lift any warrior, angel or family up with their prayers and intentions. Whether urgent or ongoing, Prayer Agents will be activated all over the world at your request and in particular on the first Sunday of every month when each name on The OsteoAngel & OsteoWarrior lists are read. Anyone can be a Prayer Agent regardless of faith tradition or spiritual practice. All are welcome.

**AGENT WRITERS**

Agent Writers write letters of hope and encouragement to OsteoWarriors monthly. Each Agent Writer receives a bio on each child (name, age, stage of treatment, city/state, interests/hobbies/likes, and a photo). With the information provided they compose their letters and send them to MIB Agents HQ to be mailed to OsteoWarriors from MIB Headquarters. No addresses are shared.

**HEALING HEARTS - A Bereavement Program**

Healing Hearts is a program offered by MIB, and created by grieving osteosarcoma parents who themselves needed a haven of love and comfort along with the hope of healing. While we acknowledge that our hearts will never heal after the loss of a child, we want our scars to remind us that we can experience joy alongside sadness, and together we can support each other in creating a life worth living for and with our children.

To learn more about MIB Agents or to join the Mission, visit www.MIBagents.org or email info@mibagents.org
Dear Agents,

The goal of Making it Better for kids with osteosarcoma is too big for one person, one organization to accomplish. MIB started with the Make It Better GOAL - not the plan. The no-plan plan was, and is to find a need and fill it, find the people aligned with the goal, and together serve that goal. This approach requires belief that better can and will happen when we come together with purpose around this essential goal of improving the outcomes for kids with this cancer.

We are moving ever closer to that goal with more funded research, more sharing and more connection of all OS constituents. In this fourth year of FACTOR, I know this for sure: we must rely on radical interdependence to accomplish this particular goal of Making it Better for Osteosarcoma kids. Together we already have changed osteosarcoma for better, yet there is still much more to do. Because of the collective “we” the goal is in sight on how to accomplish this goal - through data sharing platforms, an engaged community and experts all working to affect meaningful change. Change for better.

How excited and grateful we are to have you here in Phoenix for the Fourth Annual FACTOR Osteosarcoma conference! Not unlike leaving your home, lab, practice, school or job, undertaking this conference is no small feat - and one that desires the hearts and hands of many. We are grateful to our generous sponsors, tireless volunteers and vendors who have shared their time and support with us. We are incredibly appreciative of your wholehearted participation in FACTOR. Our promise is to make your time and effort worthwhile. If we at MIB can be helpful in any way, please just say the word.

With Hope,

Ann Graham
President & Osteosarcoma Survivor
(knock wood)
MIB (Make It Better) Agents
CONFERENCE NOTES
To make this conference as comfortable, safe and productive as possible.

MIB CONFERENCE AMBASSADORS
Available to assist you before and during the conference, just ask any agent wearing a yellow lanyard.

MIB SPEAKER AGENT
Check in with Casey Crossan to submit your thumb drive or for any questions with regard to your presentation.

MIB FLOOR CHIEF
Questions for the Panel may be handed to Liz Vallejo, who will present the questions to the Panel on your behalf, anonymously if you wish. If you’d like to ask your questions directly, please raise your hand for Liz to bring the microphone to you. During the session please be specific and brief. Menti.com will be available during panel discussions to ask questions digitally and anonymously if you wish.

DIGITAL ENGAGEMENT
Menti.com is a voting and presentation interaction online tool. Menti will be used for each panel discussion and OutSmarting Osteosarcoma voting. See Liz Vallejo for any questions regarding Menti.

TIMELINE
Our timeline is extremely tight. Kindly arrive a few minutes before the session start time to ensure the meeting can begin and end promptly.

ETIQUETTE
Kindly refrain from requesting medical advice or to review a specific case in this venue.

NAME BADGES
Please visibly display your badge throughout the conference.

PHOTOGRAPHY AND VIDEO RECORDING
The conference will be photographed and video recorded. Images may be used in MIB Agents promotional materials.

ELECTRONICS
Turn off or silence cell phones, PDAs, and electronic devices before each session begins.

CHECK OUT
If you plan on checking out on Saturday, please do so in the morning and store your luggage with the Bell Captain. This will avert any delay in your departure plans and avoid any late-check out fees.

MIB AGENTS FACTOR SURVEY
Please complete FACTOR survey to be passed out on Saturday afternoon and leave on the table at the end of conference. Your feedback helps us make improvements each year.

Thank you to our Hospitality Heroes whose donations have helped families attend this year’s event:
● Sarah Goobic and Josh Nickels ● Case Western University ● Nathan’s Story
GLOSSARY OF TERMS

**Allogeneic**: having different DNA. For example, if you get a bone marrow transplant from someone else, it is an “allogenic” transplant.

**Apoptosis**: programmed cell death. The process through which a cell dies in an orchestrated way.

**Autologous**: having the same DNA. For example, if your bone marrow is collected and stored, you get high-dose chemo, and then you get your own bone marrow back, this is called an “autologous” bone marrow transplant.

**Autophagy**: literally self-eating. A way cells consume themselves in order to survive or eventually die.

**CAR T-cell**: Chimeric Antigen Receptor T-cell, a subtype of white blood cells that are engineered to recognize and attach specific targets, ideally targets unique to a cancer.

**Checkpoint**: (a.k.a. Immune checkpoint) one of several protein cells have on their surface that tell the body's defenses (immune system) not to attack them. Several cancers hijack these proteins as a way to avoid getting attacked by the immune system.

**Checkpoint Inhibitor**: an antibody (i.e. a sort of ‘heat seeking missile’ that the body makes that attach to specific proteins on infectious organisms or cells designed to specifically attach to immune checkpoint proteins so they don't block the body's defenses (immune system) from attacking cancer cells.

**Cytotoxic**: toxic to cells.

**En vivo**: within a living being or organism (e.g. a drug tested in a patient is tested en vivo).

**Ex vivo**: outside of a living being or organism (e.g. taking a biopsy of a tumor and testing it against a drug in a petri dish or test tube is ex vivo testing of the drug).

**Exomes**: the part of DNA that is actively used by the cell. Large parts of the Genome, which is all of the DNA, are coiled up for storage and not active. The Exome is the part that is actively doing things driving the cells.

**Heterogeneous**: mixed, varied, not uniform.

**Histological**: related to how something looks under a microscope.

**Immunotherapy**: treatments that use the body's defenses (immune system) to fight cancer.

**Lymphocyte**: subtype of white blood cells. Part of the “adaptive immune system” that is able to learn and adapt to infections etc.

**Macrophages**: a subtype of white blood cells that help stimulate or suppress other white blood cells within the body.

**Mesenchymal**: related to the connective tissues in the body (bone, muscle, fat etc.).

**Microenvironment**: the microscopic environment around cells and tumors that includes the oxygen level, blood supply, acidity, and what other cells are located there.

**NK cell**: Natural Killer cell, a subtype of white blood cells that help fight infections and are believe to be important in removing abnormal cells such as cancer cells.

**Osteoid**: the matrix cells lay down that is calcified to create bone.

**Osteoblastic**: of or related to creating new bone.

**PDX Models**: Patient Derived Xenograft models. A living model used to testing tumors and drugs created by taking a piece of the patient's tumor and implanting it in an animal, typically a mouse, who has been engineered to allow the tumor to grow within that animal.

**Precision medicine**: techniques used to tailor therapy to a specific tumor based on mutations or sensitivities found within that specific tumor.

**Refractory**: another word for resistant or not responding to treatment.

**Thoracotomy**: surgery performed on the chest (a.k.a. thorax).

**VATS**: Video Assisted Thoracoscopic Surgery, surgery performed on the chest, using a small camera inserted through small openings made in the chest wall.
AGENDA: THURSDAY, FEBRUARY 27TH

10:00 AM - 4:00 PM
AMBASSADOR AGENT TRAINING
Ambassador Agent Training lunch from 12-12:30 PM

12:00 - 6:00 PM
REGISTRATION OPENS
Located in the Lobby

4:00 - 4:30 PM
MIB FAMILY FUND HOLDERS MEETING
By invitation only

4:30 - 5:00 PM
COOPERATIVE OSTEOSARCOMA FUNDRAISING
All registered FACTOR guests are welcome

5:00 - 6:00 PM
WELCOME RECEPTION
All registered FACTOR guests are welcome

5:00 - 5:20 PM
OSTEOWARRIOR VS. DOCTOR CHALLENGE
All registered FACTOR guests are welcome

6:00 PM
DINNER ON OWN - KITCHEN WEST
MIB section available for community dining - not hosted by MIB

6:15 PM
SHUTTLE DEPARTURE FOR SPEAKER DINNER
Meet at the McDowell Building

7:00 - 9:30 PM
SPEAKER DINNER
By invitation only, Off-site at Wrigley Mansion
Sponsored by the Childhood Cancer Project

OsteoWarriors HQ Happenings
(page 8)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 - 7:45 AM</td>
<td>BREAKFAST AND REGISTRATION</td>
<td>Sponsored by St. Baldrick's</td>
</tr>
<tr>
<td>8:00 - 8:10 AM</td>
<td>WELCOME AND OPENING REMARKS</td>
<td>Ann Graham, MIB Agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Matteo Trucco, MD, MIB Agents, Cleveland Clinic</td>
</tr>
<tr>
<td>8:10 - 8:20 AM</td>
<td>SESSION 1: NEW TARGET AND APPROACHES</td>
<td>Joshua Schiffman, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Utah, Huntsman Cancer Institute</td>
</tr>
<tr>
<td>8:20 - 8:40 AM</td>
<td>OUTSMARTING OS WINNER 2017 - EPS5 PROTEIN LOADED NANOPIRATE FOR OS - UPDATE</td>
<td>Joshua Schiffman, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Utah, Huntsman Cancer Institute</td>
</tr>
<tr>
<td>8:40 - 9:00 AM</td>
<td>TARGETING IGF2R IN OS WITH RADIOIMMUNOTHERAPY - COMPARATIVE ONCOLOGY APPROACH</td>
<td>Ekatarina Dadachova, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Saskatchewan, Fedoruk Center for Nuclear Innovation</td>
</tr>
<tr>
<td>9:00 - 9:20 AM</td>
<td>MAKING THE MOST OF TISSUE SAMPLES TO SUPPORT RESEARCH AND CLINICAL CARE</td>
<td>Alanna Church, MD, MSc, FRCP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Harvard Medical School, Boston Children's Hospital</td>
</tr>
<tr>
<td>9:20 - 9:40 AM</td>
<td>POSTER SESSION* &amp; BREAK</td>
<td>Sponsored by OS Collaborative</td>
</tr>
<tr>
<td>9:40 - 10:00 AM</td>
<td>UHRF1 AS A THERAPEUTIC TARGET IN OS</td>
<td>Claudia Benavente, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of California, Irvine, Chao Comprehensive Cancer Center</td>
</tr>
<tr>
<td>10:00 - 10:20 AM</td>
<td>COUNT ME IN; LAUNCHING THE OS PROJECT</td>
<td>Corrie Painter, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Broad Institute of MIT &amp; Harvard, Count Me In</td>
</tr>
<tr>
<td>10:20 - 10:40 AM</td>
<td>MAKE THE WANDERING TUMOR CELLS UNCOMFORTABLE</td>
<td>Ryan D. Roberts, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nationwide Children's Hospital</td>
</tr>
<tr>
<td>10:40 - 11:00 AM</td>
<td>PANEL DISCUSSION</td>
<td>Moderator: Schiffman</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dadachova, Church, Benavente, Painter, Roberts</td>
</tr>
<tr>
<td>11:00 - 11:15 AM</td>
<td>GROUP PHOTO</td>
<td></td>
</tr>
<tr>
<td>11:20 - 12:30 PM</td>
<td>LUNCH</td>
<td>Sponsored by Matthew Lehrman Osteosarcoma Fund</td>
</tr>
<tr>
<td>12:30 - 12:40 PM</td>
<td>SESSION 2: NEW CHEMOTHERAPY TRIALS FOR OS</td>
<td>Richard Gorlick, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Texas at MD Anderson, Children's Cancer Hospital</td>
</tr>
<tr>
<td>12:40 - 1:00 PM</td>
<td>OUTSMARTING OS WINNER 2018 - DUSILIRAM TO OVERCOME CHEMOTHERAPY RESISTANCE IN SARCOMAS</td>
<td>Matteo Trucco, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cleveland Clinic, Children's Cancer Innovative Therapy Program</td>
</tr>
<tr>
<td>1:00 - 1:20 PM</td>
<td>CHILDREN'S ONCOLOGY GROUP OS CLINICAL TRIALS PAST, PRESENT, AND FUTURE</td>
<td>Katherine A. Janeway, MD, MMSc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Harvard Medical School, Dana-Farber/Boston Children's Cancer</td>
</tr>
<tr>
<td>1:20 - 1:40 PM</td>
<td>TOWARD GENOME-INFORMED COMBINATION THERAPY FOR OS</td>
<td>Alejandro Sweet-Cordero, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Benioff UCSF, University of California, San Francisco</td>
</tr>
<tr>
<td>1:40 - 2:00 PM</td>
<td>EUROPEAN CLINICAL TRIALS &amp; APPROACHES TO OS</td>
<td>Stefan Bielack, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stuttgart Cancer Center</td>
</tr>
<tr>
<td>2:00 - 2:20 PM</td>
<td>IMPACT OF ADJUVANT SIROLIMUS ON METASTATIC PROGRESSION IN CANINE OS</td>
<td>Amy LeBlanc, DVM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>National Cancer Institute's Comparative Oncology Program</td>
</tr>
<tr>
<td>2:20 - 2:40 PM</td>
<td>REGULATORY LANDSCAPE AND IT'S IMPACT ON PHARMACEUTICAL COMPANY'S APPROACH TO PEDIATRIC</td>
<td>Mark Kieran, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>2:40 - 2:50 PM</td>
<td>PANEL DISCUSSION</td>
<td>Moderator: Gorlick</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trucco, Janeway, Sweet-Cordero, Bielack, LeBlanc</td>
</tr>
<tr>
<td>2:50 - 3:10 PM</td>
<td>POSTER SESSION* &amp; BREAK</td>
<td>Sponsored by MSK Kids, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>3:10 - 3:20 PM</td>
<td>OUTSMARTING OSTEOSARCOMA FINALISTS</td>
<td>John Healey, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>3:20 - 3:40 PM</td>
<td>CLONALITY AND MECHANISMS OF RESISTANCE TO TARGETED THERAPY IN OS</td>
<td>Richard Gorlick, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Texas at MD Anderson, Children's Cancer Hospital</td>
</tr>
<tr>
<td>3:40 - 4:00 PM</td>
<td>MODELING AND TARGETING MYC-DRIVEN OS</td>
<td>Jason Yustein, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Baylor College of Medicine, Texas Children's Cancer</td>
</tr>
<tr>
<td>4:00 - 4:20 PM</td>
<td>DEFINING THE IMMUNE ATLAS IN OS LUNG METASTASES</td>
<td>J. Andrew Livingston, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Texas at MD Anderson, Children's Cancer Hospital</td>
</tr>
<tr>
<td>4:20 - 4:30 PM</td>
<td>CLOSING REMARKS</td>
<td></td>
</tr>
<tr>
<td>6:00 - 7:00 PM</td>
<td>BEREAVED PARENT'S SESSION</td>
<td>Sandra Howlett, EdD</td>
</tr>
<tr>
<td>7:00 - 9:00 PM</td>
<td>BEREAVED PARENT'S DINNER</td>
<td>Private Event, Prayer by Deacon Smith</td>
</tr>
<tr>
<td>7:10 - 9:10 PM</td>
<td>DINNER</td>
<td>All registered FACTOR guests are welcome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prayer by Deacon Smith</td>
</tr>
</tbody>
</table>

*Poster Session sponsored by Vuja De Sciences
AGENDA: SATURDAY, FEBRUARY 29TH

6:45 - 7:45 AM  BREAKFAST

8:00 - 8:05 AM  OPENING REMARKS
Matteo Trucco, MD, MIB Agents, Cleveland Clinic

8:05 - 8:10 AM  SESSION 4: INTRODUCTION OF KEYNOTE SPEAKER
ALEX HUANG, MD, PHD
Matteo Trucco, MD
Cleveland Clinic, Children's Cancer Innovative Therapy Program

8:10 - 8:30 AM  KEYNOTE SPEECH: OUTSMARTING OS 2019 WINNER - CONDITIONING THE IMMUNE ENVIRONMENT FOR EFFECTIVE THERAPIES FOR METASTATIC PULMONARY OS
Alex Huang, MD, PhD
Case Western Reserve University School of Medicine, Rainbow Babies & Children's Hospital

8:30 - 8:40 AM  KEYNOTE SPEECH: Q & A
Alex Huang, MD, PhD
Case Western Reserve University School of Medicine, Rainbow Babies & Children's Hospital

8:40 - 9:00 AM  POSTER SESSION* & BREAK

9:00 - 9:10 AM  SESSION 5: IMMUNOTHERAPY & MICROENVIRONMENT/METASTATIC DISEASE
Alex Huang, MD, PhD
Case Western Reserve University School of Medicine, Rainbow Babies & Children's Hospital

9:10 - 9:30 AM  CAR-T CELL THERAPY FOR OS AND PEDIATRIC SOLID TUMORS
Robbie Majzner, MD
Stanford University, Stanford University Medical Center

9:30 - 9:50 AM  TUMOR VACCINE FOR CANINE OS
Brian K. Flesner, DVM, DACVIM
University of Missouri, College of Veterinary Medicine

9:50 - 10:10 AM  DC VACCINE AND TGFβ AS IT MAY RELATE TO OS
John Letterio, MD
Case Western Reserve University School of Medicine, Rainbow Babies & Children's Hospital

10:10 - 10:30 AM  EMERGING CELLULAR THERAPIES FOR OS
Kris Mahadeo, MD, MPH
University of Texas at MD Anderson, Children's Cancer Hospital

10:30 - 10:40 AM  PANEL DISCUSSION
Moderator: Huang
Majzner, Flesner, Letterio, Mahadeo

10:40 - 11:35 AM  SESSION 6: ALL THINGS MIB AGENTS
Liz Vallejo, Casey Crossan, Maureen Smart, LCSW, Sean Brosnan, Bentley Dyer, Tim Songster, Alexis Johnson, Maeve Smart, and Christina Ip-Toma
MIB Agents

11:35 - 12:45 PM  LUNCH

12:45 - 1:00 PM  SESSION 7: THE OS INSTITUTE: WHO WE ARE, WHAT WE DO, AND WHERE WE ARE GOING
Lee Helman, MD
USC Keck School of Medicine, Children's Hospital of Los Angeles

1:00 - 1:20 PM  TARGETING METASTATIC DEPENDENCIES IN OS
Peter Scacheri, PhD
Case Western Reserve University

1:20 - 1:40 PM  CD73 - THE NEXT IMMUNOTHERAPY TARGET IN OS
J. Andrew Livingston, MD, MS
University of Texas at MD Anderson, Children's Cancer Hospital

1:40 - 2:00 PM  GENOME-INFORMED COMBINATION THERAPY IN OS
Katherine A. Janeway, MD, MMSc
Harvard Medical School, Dana-Farber/Boston Children's Cancer and Blood Disorder Center

2:00 - 2:10 PM  PANEL DISCUSSION
Moderator: Helman
Scacheri, Livingston, Janeway

2:10 - 2:30 PM  POSTER SESSION* & BREAK

2:30 - 2:40 PM  SESSION 8: SUPPORTIVE CARE AND MINIMIZING TOXICITY
Peter Anderson, MD, PhD
Cleveland Clinic, Children's Cancer Innovative Therapy Program

2:40 - 3:00 PM  PARENTAL REGRET, DECISION MAKING AND COMMUNICATION
Bryan Sisk, MD
Washington University School of Medicine

3:00 - 3:20 PM  SURGICAL DECISION AID FOR THE TREATMENT OF OS IN THE LOWER EXTREMITY
Janet Panoch, MA
Amputee Coalition

3:20 - 3:40 PM  SURVIVING AND THRIVING: PHYSICAL AND OCCUPATIONAL THERAPY FOR PATIENTS WITH OS
Christine Zwick, DPT & Chelsea Derkacz, OTR
Nemours/Alfred I. duPont Hospital for Children

3:40 - 4:00 PM  CARING FOR THE HEALTHCARE TEAM
Kate Eshelman, PsyD
Cleveland Clinic Children's Hospital

4:00 - 4:20 PM  PROMOTING QOL OUTCOMES FOR OS PATIENTS THROUGH SMART AUDIO COMPANIONSHIP
Simon Holland
Ely Health

4:20 - 4:30 PM  PANEL DISCUSSION
Moderator: Anderson
Sisk, Panoch, Zwick, Derkacz, Eshelman, Holland, Ramer

4:30 - 4:55 PM  SESSION 9: ANNOUNCEMENT OF OUTSMARTING OS WINNER
Matteo Trucco, MD and MIB Family Fund Holders

4:55 - 5:00 PM  CLOSING REMARKS
Ann Graham and Matteo Trucco, MD
MIB Agents

5:45 - 9:30 PM  PHOENIX SUNS GAME
Tickets must have been purchased in advance, ticketholders depart at 5:45 PM

*Poster Session sponsored by Vuja De Sciences
AGENDA: SUNDAY, MARCH 1ST

- 7:00 - 7:30 AM
  OUTRUNNING OSTEOSARCOMA 5K REGISTRATION
  All runners
- 7:30 - 8:00 AM
  WARM UP AND STRETCH
  All are welcome!
- 8:00 - 10:00 AM
  KID DASH AND 5K

OSTEOWARRIOR HEADQUARTERS (HQ)
Located at Palm Court/Sunset on the second floor, next to elevators

Thursday, February 27th
- 5:00 - 5:20 PM
  OSTEOWARRIORS VS. DOCTORS CHALLENGE
  Bennie’s Courtyard
- 5:20 - 6:00 PM
  SCAVENGER HUNT
  Meet in HQ
- 6:00 - 10:00 PM
  DINNER & HANGING OUT
  Pizza Party
- 7:00 - 9:00 PM
  CARICATURES
  Colorbox Entertainment

Friday, February 28th
- 6:45 - 7:50 PM
  BREAKFAST
  Breakfast with all FACTOR attendees
- 8:00 - 9:00 AM
  CONTINENTAL BREAKFAST
  Pastries & Cereal
- 8:30 - 10:30 AM
  POTTERY PAINTING
  As You Wish Pottery
  Make & Take
- 10:30 - 12:30 PM
  POOL PARTY & LUNCH
- 12:30 - 3:30 PM
  HAIR, MAKE-UP
  Sirce Beauty
- 1:30 - 4:30 PM
  WARRIOR/FAMILY PHOTO SESSION
  Christine Johnson Photography
- 2:30 - 4:30 PM
  JUGGLING
  Dangerously Fun Juggling

Saturday, February 29th
- 6:45 - 7:50 PM
  BREAKFAST
  Breakfast with all FACTOR attendees
- 8:00 - 9:00 AM
  CONTINENTAL BREAKFAST
  Pastries & Cereal
- 9:00 - 11:00 PM
  ARTS & CRAFTS - DREAMCATCHERS
  Pinspiration Phoenix
- 11:00 - 1:00 PM
  POOL PARTY & LUNCH
- 1:00 - 4:30 PM
  CAKE DECORATING
  Cakes By Whisk
- 4:15 - 5:00 PM
  TRANSPORTATION TO NBA GAME
  Meet in Motor Lobby
- 5:00 - 6:30 PM
  PRE-GAME WITH THE PHOENIX SUNS
  Main Court
- 6:30 - 6:50 PM
  DINNER FROM CONCESSION STANDS
- 7:00 - 9:30 PM
  SUNS V. GOLDEN STATE WARRIORS!
- 8:00 - 8:15 PM
  OSTEOWARRIOR EXPERIENCE AT GAME
- 9:30 - 10:15 PM
  TRANSPORTATION TO HOTEL

Thank you to the Mason Chandler Allen Memorial Foundation for sending the HQ OsteoWarriors to the Phoenix Suns game.

See www.mcamf.org for information about FACTOR, our annual membership campaign.
MIB AGENTS FAMILY FUNDS

MIB Agents is an alliance of osteosarcoma friends and families who have committed to the improvement of osteosarcoma outcomes in a direct and impactful way. It’s because of these families that we are able to accomplish missions great and small, and fund osteosarcoma research.

ALLEN DEDON
OSTEOSARCOMA RESEARCH FUND

ANDREW BISAGA
OSTEOSARCOMA RESEARCH FUND

BRIANA LOEDING
OSTEOSARCOMA RESEARCH FUND

CAMERON BOTTELBERGHE
OSTEOSARCOMA RESEARCH FUND

CHEYENNE DEVELASCO
OSTEOSARCOMA RESEARCH FUND

CHRIS TAYLOR
OSTEOSARCOMA RESEARCH FUND

CHRISTIEN MIKHAIL QUILES
OSTEOSARCOMA RESEARCH FUND

CLAYTON LAUPUS
OSTEOSARCOMA RESEARCH FUND

CONNER CROSSAN
OSTEOSARCOMA RESEARCH FUND

To learn more about a Family Fund, simply take a photo of QR code with your phone.
To learn more about a Family Fund, simply take a photo of QR code with your phone.

If you would like to start a fund in honor of your OsteoWarrior or OsteoAngel, contact Casey at Casey@MiBagents.org or visit www.MiBagents.org/create-fund
Why Have a Family Fund Through MIB Agents:

- Every dollar raised goes as a whole dollar to help kids with osteosarcoma.
- When your fund reaches $5,000 or more in our funding year (Jan 1 - Dec 31) the family will be invited to our OutSmarting Osteosarcoma meeting to be an active participant in choosing promising osteosarcoma research initiatives to fund $100,000.
- By raising $5,000 your child's name will also appear on the check presented to the $100,000 grant winner.
- Give your community an outlet to get involved in helping your warrior and others just like them.
- No setting up a 501c3, getting a board, etc.– MIB Agents has done all the leg work so you don't have to! Which lets you focus on the more important things like fundraising and helping Make It Better for kids with osteosarcoma.

What MIB Agents Does:

- Once MIB Agents has received your application we will set up a fundraising page on our website with a dedicated URL.
- You can update or make any changes to your fundraising page by emailing Casey@MIBagents.org.
- Once the page is live you can share it with family and friends.
- A detailed report can be requested at any time and all individuals donations will be forwarded to designated individuals of your choosing within 24 hours of being received by MIB Agents HQ.
- All donors will receive a receipt for their taxes.

The Process:

To set-up a family fund fill out application at www.MIBagents.org/create-fund with the following information:

- Photo of your OsteoWarrior
- A brief summary of their story
- A title for your fund page, for example, “Sarah’s Osteosarcoma Fund”
- A short thank you message to donors
- Select type of fund:
  - General: This is the best way you can help kids with osteosarcoma. A general fund will allocate funds to where it is needed most. Not only will it help fund meaningful research it may also help complete a mission or a number of other initiatives that MIB Agents undertakes.
  - Missions and Programs: Designating your fund to Missions and Programs allows your funds to directly impact the end-of-life missions we undertake as well as the programs we offer to patients and their families (Ambassador Agents, Gamer Agents, and Agent Writers)
  - Osteosarcoma Research: All the funds raised will go towards funding meaningful osteosarcoma research.

For more information, please visit our website or find Briana or Casey who can help too!
A Super Hero Event for Kids with Cancer

Outrunning Osteosarcoma
5K and Kid Dash

★ All-Ages!
★ Free Shirt
★ Medals for Fastest Finishers!
★ Strollers and Walkers Welcome!

Sun, 3/1/2020
Scottsdale, AZ
Run, Walk or Fly!

Still time to register, see registration table for info
Registration: 7AM
Start Time: 8AM

Register & Fundraise, or Donate:
www.MIBagents.org/Outrunning-osteosarcoma

The Childhood Cancer Project
Developing Cures. Delivering Hope.
Cem Yelmen
Cecilia Nguyen
Catherine Kelly
Caroline Richards
Carson Sumpter
Carlo Minasi
Carson Bottelberghe
Cailin Capri Cannella
Brooks Paul
Brooke Foster
Brock Gumm
Briana Loeding
Brian George
Brennan Houghton
Brandon Hendrick
Brandon Gordon
Brandon Grier
Brandon Brotoamodjo
Brandon DuPont
Branden Houghton
Brain George
Brainna Loeding
Brooke Gumm
Brooks Paul
Bailin Capri Cannella
Cameroon Bottelberghe
Carlo Minasi
Carson Sumpter
Caroline Richards
Carver Mock
Catherine Kelly
Cecilia Nguyen
Cem Yelmen

Chance Rodgers
Chase Bailey
Chelsea Ebert
Cheyenne DelVallesco
Chris Hailey
Chris Taylor
Christie Hanovnikian
Christies Michael Quilles
Claire Moody
Clayton
Colleen Moore
Collin Rounds
Conner Crossan
Cullen Keltis
Damon "Super D" Billeck
Dan Keneawy
David Garcia-Beech
Daniel Stanley
Darian King
Darren Vink
David Jacobsohn
David Gulko
David Robbins
Devon Currie
Doug Brown
Drew Thomas Martin
Drew Hilliard
Dustin Smith
Dylan McCabe
Earl Cook
Eliah Aleman
Emily Del Vecchio
Emma Koeserken
Emmanuel Kwanie Ayegman
Ethan Fox
Eve Eriksen Richards
Faith Sfizer
Fiona Morris
Gabriel Taylor
Gabriella Castillo
Garrett Starper
George Bertoli
Gina Lynne Schell
Grant McGarry
Greg Vinn Rueden
Gordon Shields
Hallie Anne Brown
Heidi Tolo Merkel
Heath Sammon
Hunter Spurgeon
Ian Vallejo
Jacob Maloy
Jake Cavanaugh
James Hayden
James McMillan
James Schwerin
James Pagan
Jana Wang
Janina Vargas
Jared
Jared Hollingsworth
Jayden Isaiah Ojeda
Jayden Thompson
Jaylen Winzer
Jayme Ax
Jenny Telling
Joe Friend
Joern Wistesen Andersen
John Gibenho – brother
Jonah Chrisman
Jonathan E Faure
Jordan Jacques
Jordan Wright
Joseph Strong (Joe Ibanez)
Jori Zemel
Josh Deaton
Josh Harvey
JR Burnett
Justice Cowen
Justin Stipa
Kaitlyn Bernhardt
Kalali Peter
Karmas Maestas
Katherine Spring
Katie Elliot
Katie Roger
Katie Wilson
Karen McMurray
Keegan Fletcher
Kellie Lucas
Kellen
Kelvin
Kemper Angelo Gonzales
Vergara
Kennedy Griffith
Kennett Mobil
Kyle Ashley
Kyle Brustovicz
Kyle Patrick Egan
Kyle Miller
Kyra Root
Lance Hausfeldt
Lane Cooper
Laura Stewart
Lauren Woody
Lauren Smith
Lena (Denmark)
Lena Leonard
Leon Huhn
Lewis Bryant Jr.
Liddy Shriver
Lily Anderson
Lindsey Wilkins
Lisa Harder
Lisa Rowan
Logan Boyd
Luke Lafrray
Luke Simon
Mac Graham
Mackenzey Kenzi Larson
Maddie Lane Demers
Madeline Parker Higgins
Malcolm Hill
Marc Nieuwburg
Maddie Lenge
Marshall Smith
Mason Wilson
Mason Chandler Allen
Mathias Giordano
Matt Clevenger
Matthew Lehrman
Matt Siegel
Matt Brown
McKenna Rae Schummer
Megan Holmes
Michael Heras
Michael "Tank" Pacheco
Mikayla Rose Adams
Miranda Ram-Nolte
Miyi Nors
Mohler
Mohann Anand
Morgan Anderson
Muriel Walters
Muai
Naja Symone McCutchin
Natalie Hill
Nathan Noel Burgess
Nathan Silpath
Nick Wirawan
Nick Widner
Nazar
Nicholas Reamer
Nikolas Floyd
Nicholas Kroeger
Nicholas Reamer
Nick Mendez
Nikki Jenkins
Oliver Feldman
Olivia "Livy" Lear
Owen Wicks
Paul Yared
Patrick Battle Jr.
Patrick Frisland
Rachel Collett
Randy Bultena
Raul Buelvas
Rick Szabel
Ronald Alego
Rory Zinna
Ryan Tinny
Sabina Marullo
Safnamol Voosas
Salute Lauti
Sam Bish
Sam Merkel
Samantha Ashburn
Sammie Hartfield
Sara Corbello
Sarah Maria Brauser Hays
Sarah Swanson
Scott Shockley
Seth Bombed
Seth H. Brooks
Seth Wright
Shane Christiansen
Shane Schuster
Shannon Casey
Shannon Wilkes
Sharon Roloff
Shayla Holwegner
Sheryl Lunde
Sid Ortino
Sienna Hgbee
Soren Fairburn
Soren Vestergaard
Steve Knit
Steve Long
Tanner
Tasha "Shay" Clayton
Tate Michael
Tawnya Phillips
Tim Klotz
Tucker Judd Helstrom
Todd Andreas
Tom McCauley
Travis White
Tyler Baker
Tyler Keaton
Tyler Markus
Tyler Musselwhite
Tyler Keeton
Tyler Baker
Tyler Keaton
Tyler Musselwhite
Uwen Chen
Will Krajewski
Will Mirt
William Maki
Willie Tichenor
Zach Ireland
Zach Boistei
Zack Sohor
Zane Jacobsen
Ziggy

Osteo Angels
Believe in Better

“This painting of a hot air balloon rising above the clouds represents my belief that we can make it better for kids with osteosarcoma. I painted the sky darker on the bottom which represents where we are with osteosarcoma treatments today. My hope is that like to rising hot air balloon, together we can make it better and rise into lighter skies.”

Elise Robinson, Age 13, Texas
Diagnosed with osteosarcoma in 2014 at 8 years old
THE OSTEOSARCOMA INSTITUTE WILL DEVELOP AND EXECUTE A COMPREHENSIVE, RATIONAL STRATEGY TO IMPROVE DRAMATICALLY THE LIFE EXPECTANCY OF RELAPSED AND METASTATIC PATIENTS.

The doctors, researchers and advocates who make up the Osteosarcoma Institute have all experienced the devastation of osteosarcoma firsthand through their work, families, and friends. We have prioritized three areas for investment.

- Identify effective new drugs and drug combinations by funding clinical trials in recurrent and metastatic osteosarcoma.

  *What we've done:* OSI is funding an immunotherapy clinical trial in recurrent osteosarcoma and will announce funding for a second clinical trial next year.

- Gain insight by identifying and funding pre-clinical studies of translationally-relevant unknowns that are impeding progress.

  *What we've done:* OSI has committed to fund a biology study investigating inhibition of CDK12, a protein involved in cell division that, in preclinical models, has been shown to be critical for osteosarcoma metastasis to the lungs. We will announce funding for a second preclinical, translational study next year.

  Additionally, we make available to pharmaceutical and biotechnology companies a bank of osteosarcoma cell lines for evaluating whether new drugs they are developing are active against the disease.

- Raise awareness of osteosarcoma.

  *What we've done:* [www.osteosarcoma.info](http://www.osteosarcoma.info)

  The Osteosarcoma Information Hotline, sponsored by OSI, offers patients and their families free access to expert advice and guidance through the complex decisions that come with an osteosarcoma diagnosis.

  *(833) 801-3435*
Peter Anderson, MD, PhD
Pediatric Hematology/Oncology, Cleveland Clinic
MIB Agents Board of Directors
MIB Agents Scientific Advisory Team

Dr. Anderson graduated summa cum laude from the University of Minnesota, then began an MD, PhD program. This was completed at Mt. Sinai School of Medicine and City University of New York (Biochemical Genetics). Anderson then did a combined Internal Medicine/Pediatrics residency at Duke and Fellowship in Peds Heme/Onc/BMT at the University of Minnesota – where he had a lab and obtained 3 patents. He then spent 10 years at Mayo (promoted to Professor) and was involved in some innovative osteosarcoma clinical trials including the use of samarium. He was at MD Anderson Cancer Center 2005-2014 and tested mifamurtide, anti-IGFR, samarium, and 223Ra against osteosarcoma. Now at Cleveland Clinic, he remains active in patient advocacy and novel approaches to care of patients with sarcomas, especially osteosarcoma.

What Do You Hope For:
“Summarize what I have learned from other speakers’ insights, Share how to communicate what is needed for osteosarcoma patients & caregivers, Have audience vote on what is important to them to “Make it Better”

Prof. Stefan Bielack, MD
Pediatric Hemato-Oncologist
Head of the Department of Pediatric Oncology, Hematology, Immunology at the Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany

Professor Stefan Bielack is a pediatric hemato-oncologist and head of the Department of Pediatric Oncology, Hematology, Immunology at the Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany. His main scientific and clinical interest lies in the field of bone sarcoma, particularly osteosarcoma. He is chairman of the Cooperative German-Austrian-Swiss Osteosarcoma Study Group, COSS, was ECT project leader of the European and American Osteosarcoma Study, EURAMOS1, and leader of the bone tumor work package of the European Network for Cancer Research in Children and Adolescents, ENCCA. In 2016, he was awarded the German Cancer Prize (Deutscher Krebspreis) for his clinical research on bone sarcoma. Stefan Bielack currently holds the position of Treasurer of SIOPE, The European Society of Pediatric Oncology Europe. He has previously served as President of the European Musculo-Skeletal Oncology Society, EMSOS, and as board member of the German Society for Pediatric Oncology and Hematology, GPOH, and the Southern German Society for Pediatric and Adolescent Medicine, SGKJ. He is a current member of the editorial boards of Cancer Treatment Reviews and the Journal of Adolescent and Young Adult Oncology and has previously served as an editorial board member for the Journal of Clinical Oncology. Stefan Bielack is a member of the ESMO Sarcoma Faculty and Co-Chair of the ESMO-SIOPE Joint Working Group on Cancer in Adolescents and Young Adults.

Claudia A. Benavente, PhD
Assistant Professor
Department of Pharmaceutical Sciences
Department of Developmental and Cell Biology, Chao Family Comprehensive Cancer Center, University of California, Irvine

Dr. Benavente studied Molecular Biotechnology Engineering at Universidad de Chile where her interest in cancer research first started. She moved to the US to pursue a doctoral degree in Cancer Biology at The University of Arizona as a Fulbright scholar. As a postdoctoral fellow at St. Jude Children’s Research Hospital in Memphis, TN she became familiarized with childhood solid tumors. In 2014, Professor Benavente joined the Departments of Pharmaceutical Sciences and Developmental and Cell Biology and became a Member of the Chao Family Comprehensive Cancer Center at the University of California, Irvine. Her research aims to understand how genes are normally controlled in developing tissues and how genetic and epigenetic processes are perturbed to facilitate cancer, particularly in childhood cancers. This information guides her in the development of new therapies. Dr. Benavente research is funded by the NIH/NCI, ACS, AACR-Aflac Inc., and UCI.

Alanna J. Church, MD
Associate Director, Laboratory for Molecular Pediatric Pathology (LaMPP); Staff Pathologist, Department of Pathology, Boston Children’s Hospital Instructor of Pathology, Harvard Medical School

Alanna Church received her M.D. from Queen’s University in Ontario, Canada. Dr. Church completed her residency at Queen’s University and completed fellowships at Harvard Medical School, Brigham and Women’s Hospital in Boston and Boston Children’s Hospital. Dr. Church as Board Certifications for Anatomic Pathology, Molecular Genetic Pathology and Pediatric Pathology. Dr. Church is currently the Associate Director in the Laboratory for Molecular Pediatric Pathology (LaMPP) at Boston Children’s Hospital and Instructor at Harvard Medical School. Dr. Church finds genetics fascinating and was drawn to Pathology because of the intellectual challenge of understanding the diseases that affect our patients, and the molecular aspect takes it to another, deeper level. Since her focus is on pediatric solid tumors, she has launched a completely new molecular pathology laboratory to support the care of pediatric cancer patients at Boston Children’s Hospital.

What Do You Hope For:
“I am looking forward to connecting with families and researchers who are passionate about improving care for our patients with osteosarcoma. We are working hard to improve tissue allocation to support research, and we need support from patients, families and medical professionals to make it better.”
Ekaterina (Kate) Dadachova, PhD
Chair in Radiopharmacy, Fedoruk Center for Nuclear Innovation
Professor, College of Pharmacy and Nutrition
University of Saskatchewan

As of November 1st 2016, Dr. Ekaterina (Kate) Dadachova is the Fedoruk Centre for Nuclear Innovation Chair in Radiopharmacy. She was most recently a Professor of Radiology, Microbiology and Immunology in the Albert Einstein College of Medicine at Yeshiva University, where she was also the Sylvia and Robert S. Olnick Faculty Scholar in Cancer Research. She received her PhD in Physical Chemistry from Moscow State University in 1992, and completed a postdoctoral fellowship in radiopharmaceutical chemistry at the Australian Nuclear Science and Technology Organization.

What Do You Hope For:
“I am hoping that radioimmunotherapy will provide curative solutions for kids and for veterinary patients.”

Chelsea Miles Derkacz, OTR
Occupational Therapist
Nemours, A.I. duPont Hospital

Ms. Derkacz graduated Summa Cum Laude from Elizabethtown College with her masters degree in Occupational Therapy. She was the primary occupational therapist on the hematology/oncology unit at Nemours, A.I. duPont Hospital for Children for 9 years. She has participated in research with Children's Oncology Group and is interested in advancing evidence on the role of physical activity during treatment and recovery for pediatric oncology patients.

What Do You Hope For:
“As a professional working with pediatric cancer patients and as a cancer survivor myself, I hope we see a cure for ALL cancers in my lifetime.”

Kate E. Eshleman, PsyD
Pediatric Psychologist
Center for Pediatric Behavioral Health
Clinical Assistant Professor of Pediatrics
Director, Fellowship in Pediatric Behavioral Health
Cleveland Clinic

Dr. Eshleman is a pediatric psychologist at Cleveland Clinic Children's, working with infants through young adults, and their families, with acute and chronic medical conditions. She came to CCC's in 2008 to complete her fellowship, following her internship in pediatric behavioral health at Jackson Memorial Hospital. Dr. Eshleman has worked with children, adolescents, and their families with a variety of physical and associated mental health concerns, and over the last few years has transitioned into the role of psychologist for the Department of Pediatric Hematology/Oncology, where she is currently involved in clinical care and psychosocial program development. Dr. Eshleman recently received a Cleveland Clinic Caregiver Catalyst Award to develop the Sibling Outreach Program for siblings of children diagnosed with oncological or serious hematological diseases. Dr. Eshleman is actively involved in training, serving as the Director of the Fellowship in Pediatric Psychology, providing supervisions to pediatric psychology residents, overseeing Developmental and Behavioral Pediatrics training for the general pediatrics medical residents, and facilitating problem-based learning courses in the Cleveland Clinic Lerner College of Medicine. Dr. Eshleman is passionate about bioethics, and serves as the Vice Chair of the Pediatric Subcommittee of the Cleveland Clinic ethics subcommittee.

Brian K. Flesner, DVM, MS, DACVIM
Assistant Professor of Oncology
University of Missouri, College of Veterinary Medicine

Dr. Flesner has been an assistant professor and veterinary oncologist at the University of Missouri for four years and is extensively involved in the vibrant clinical trials service at the MU Veterinary Health Center. The trials service sees hundreds of patients annually; notably, 70 dogs with osteosarcoma were enrolled in osteosarcoma specific clinical trials in the past four years. Dr. Flesner is currently site principal-investigator for several ongoing osteosarcoma studies, including three near completion National Cancer Institute COTC nationwide trials. Mizzou has been one of the top three enrolling institutions in the country in these trials over the past few years. Dr. Flesner previously performed a medical oncology residency at MU (2011-2014) and passed the ACVIM (American College of Veterinary Internal Medicine) oncology specialty boards in June, 2014. He became faculty at Louisiana State University in 2014, before returning to Mizzou at the beginning of 2016. Besides studying osteosarcoma, Dr. Flesner's research interests include chemotherapy mechanisms of action and toxicity, cancer-induced pain, and novel chemotherapeutic approaches to combat aggressive neoplasms. He lives north of Columbia on 40 acres with the hopes of starting a small cattle herd in the near future.
Richard Gorlick, MD
Division Head and Department Chair, Pediatrics, The University of Texas MD Anderson Cancer Center Children's Cancer Hospital

Dr. Gorlick is Division Head and Department Chair of Pediatrics at The University of Texas MD Anderson Cancer Center. Dr. Gorlick received his medical degree from Downstate Medical School. He trained at New York-Presbyterian and Memorial Sloan-Kettering Cancer Center, where he began his sarcoma research laboratory and clinical practice. His laboratory is the founding Bone Tumor Resource Laboratory for the Children's Oncology Group. His molecular pharmacology laboratory is completely focused on osteosarcoma. His laboratory is a member of the NCI-funded Pediatric Preclinical Testing Consortium. Dr. Gorlick is involved in clinical trials, in part, as past chair of the Bone Tumor Disease Committee for COG. He is a past president of the Connective Tissue Oncology Society. Dr. Gorlick has published more than 260 peer-reviewed papers, reviews and book chapters.

Best Thing About The FACTOR Conference:
“The FACTOR Conference is unique in that it brings together parents, patient advocates, providers, the scientific community and others to share common issues and research advances, and to remember our common struggles against osteosarcoma.”

Ann Graham
President and Founder
MIB Agents & FACTOR Conference
Osteosarcoma Survivor

Ann is the founder and President of MIB Agents Osteosarcoma Alliance. At age 43, Ann was diagnosed with osteosarcoma and was treated in the Pediatric Center at Memorial Sloan Kettering Cancer Center. She was in awe of the courage of her fellow patients. Like most, she was unaware of how little funding pediatric cancers receive, and that osteosarcoma patients lose limbs, fertility, hearing, organ function and too often, their lives. She knew there had to be a way to Make It Better. She began MIB Agents, a nationwide 501c3 non-profit and the FACTOR Conference. Together with MIB Agents everywhere, they endeavor to Make It Better for osteosarcoma patients. She is an Advocate with the A2A Alliance, The Mighty, and a member of CAC2.

John H. Healey, MD, FACS
Chief, Orthopaedic Service; Stephen McDermott Chair in Surgery
Memorial Sloan Kettering Cancer Center
MIB Agents Board of Directors
MIB Agents Scientific Advisory Team
Editor: Osteosarcoma: From Our Family to Yours

I have decades of experience diagnosing and treating sarcomas and benign tumors of the bones and soft tissue. I am an expert in surgery to remove tumors while preserving limbs, and I rebuild functional bones and joints with joint replacements and bone transplants. I also have a special interest in treating children who have bone cancers (osteosarcoma and Ewing sarcoma). As we continue to make progress in curing these cancers, it becomes even more important to be able to reconstruct limbs to provide patients with optimal long-term function. While our goal is always to cure the cancer, we strive to understand each patient’s activities and help them achieve their individual goals while maintaining hope for the future. My research involves understanding the molecular biology of sarcoma, developing new ways to deliver chemotherapy to tumors, and improving the durability and function of joint replacements. I have invented and developed four different joint replacement systems and have patented several methods to deliver drugs to tumors and to study cancers in the laboratory. In addition to my role as Chief of the Orthopaedic Service at Memorial Sloan-Kettering, I am a Professor of Orthopaedic Surgery at Weill Cornell Medical College. Nationally, I have served as Chair of the Children’s Oncology Group Orthopaedics Section, as President of the International Society of Limb Salvage, President of the Association of Bone and Joint Surgeons, and on the boards of several musculoskeletal and orthopedic organizations.

Lee J. Helman, MD
Professor, Departments of Pediatrics and Medicine, Keck School of Medicine
University of Southern California
Head, Basic and Translational Research
Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles

Lee J. Helman received his MD from the University of Maryland School of Medicine magna cum laude. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and as Scientific Director for Clinical Research in the Center for Cancer Research, NCI, from 2007-2016. He joined Children's Hospital Los Angeles and the University of Southern California in 2017 as professor of Pediatrics and Medicine at the Keck School of Medicine and director of Basic and Translational Research within the Children’s Center for Cancer and Blood Diseases at CHLA and is a member of the USC Norris Comprehensive Cancer Center. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He received the 2011 ASCO Pediatric Oncology Award and is a Fellow of ASCO. Helman was the inaugural chair of the Pediatric Oncology Working Group of AACR. He serves as vice chair of the Scientific Advisory Committee of Stand Up To Cancer. His laboratory work focuses on the biology and treatment of pediatric sarcomas, including rhabdomyosarcoma, Ewing’s, osteosarcoma, and pediatric GIST tumors. Areas of research include: pathophysiologic consequences of IGF signaling, identification of the molecular/ biochemical determinants of the biology of sarcomas, and the application of functional genomics to identify new treatment targets.
Simon Holland spent his childhood between Peru, Australia and Spain, and was exposed to a diverse array of people, places and culture. Bringing these eclectic experiences into adulthood, he studied Entrepreneurship at RMIT in Melbourne. Simon has applied his knowledge of design, strategic thinking and defining a clear purpose to over 50 startups. He believes the entrepreneurial struggle is an opportunity for innovative thinking. He used this passion to help fledgling startups grow and find a product-market fit. Simon co-founded HotDoc, Australia’s largest patient engagement platform used by almost 5 million patients, as well as Vivi which is a screen mirroring solution for education. In 2019 Simon moved to Los Angeles to co-found Elly, an empathetic audio companion for patients living with a chronic disease.

Dr. Sandi Howlett is a teacher and life-long learner specializing in bereavement. She has extensive experience with bereavement through her work as Bereavement Special with Hansen Mortuary for 14 years including facilitating grief support groups as well as 1:1 client support, her 16-year affiliation with New Song Center for Grieving Children as facilitator and as part of the training faculty as well as teaching for the American Hospice Foundation and a variety of hospices in Arizona. She has presented at national conferences for Sudden Unexplained Death of a Child, Parents of Murdered Children, MISS Foundation and is an authorized lead facilitator for the Institute for Healing of Memories – North America. She believes that everyone can heal...though the means, time and degree vary. She applies practical wisdom, compassion and humor to assist people in finding their own healing path.

Christina Ip-Toma lives in the San Francisco Bay Area with her husband Burt and their three sons. Her youngest son Dylan was diagnosed with osteosarcoma in January 2016 when he was nine years old. After three years of many drugs and several surgeries, Dylan is still battling like a superhero. Christina is the Chief Agent in developing the Big Data chart initiative, which aims to help inform patient families of their choices in sharing this vital information.

What Do You Hope For:
“Together, we can identify promising treatment options and make them accessible for OsteoWarriors.”

Dr. Alex Huang earned B.S. / M.S. from University of Chicago and M.D./Ph.D. from Johns Hopkins University. Following a residency at Johns Hopkins Hospital, Pediatric Hematology/Oncology fellowship at Johns Hopkins / NCI, and a postdoctoral fellowship at NIAID, Dr. Huang joined Case Western Reserve University School of Medicine where he is currently tenured Professor of Pediatrics, Pathology, Biomedical Engineering, and General Medical Sciences. He holds the Theresia G. & Stuart F. Kline Family Foundation Chair in Pediatric Oncology and is the Director of the Pediatric Hematology-Oncology Fellowship Program at UH Rainbow Babies & Children's Hospital. Dr. Huang oversees immune-based cancer therapeutics at the Case Comprehensive Cancer Center. Dr. Huang’s research focuses on exploring the immune system to control metastatic cancers in pediatric and AYA patients.

Best Thing About The FACTOR Conference:
”Most impactful aspect of attending previous FACTOR meeting was the ability to have direct access and personal connection to osteosarcoma patients and families in order to put proper perspectives and sense of urgency in the work that we do in the laboratory.”
Dr. Janeway received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Pediatrics at Children's Hospital, Boston. She was a Chief Resident at Childrens Hospital, Boston, and then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute / Children's Hospital, Boston. In 2007, Dr. Janeway joined the staff of Dana-Farber and Children's Hospital, Boston, where she is a pediatric hematologist-oncologist and investigator with a research focus of pediatric sarcomas.

What Do You Hope For:
“In the future I hope to cure more of the osteosarcoma patients I take care of and, as a result, know even more OsteoWarriors who are living healthy and fulfilling lives after treatment.”

Amy LeBlanc is board-certified veterinary oncologist and the Director of the intramural National Cancer Institute's Comparative Oncology Program. In this position she conducts preclinical mouse and translational canine studies that are designed to inform the drug and imaging agent development path for human cancer patients. She also advises leading pharmaceutical companies as well as NCTI’s Division of Cancer Treatment and Diagnosis on the inclusion of pet dogs with cancer into the development path of novel approaches for a variety of malignancies, including immunotherapeutics, targeted small molecules, oncolytic viruses, and cancer imaging agents. She directly oversees the NCI Comparative Oncology Trials Consortium (COTC), which provides infrastructure necessary to connect participating veterinary academic institutions with stakeholders in drug development to execute fit-for-purpose comparative clinical trials in novel therapeutics and imaging agents.

Amy K. LeBlanc, DVM
Diplomate ACVIM
Director, Comparative Oncology Program
Center for Cancer Research,
National Cancer Institute
National Institutes of Health

John Letterio is Chief of Pediatric Hematology Oncology at University Hospitals Rainbow Babies & Children's Hospital, where he is also the Director of the Angie Fowler Adolescent & Young Adult Cancer Institute. John was recruited to Cleveland from the National Institutes of Health (NIH) in 2006, as Professor of Pediatrics at the Case Western Reserve University (CWRU) School of Medicine, and he is a co-Leader of the Developmental Therapeutics Program of the Case Comprehensive Cancer Center. Dr. Letterio earned his Bachelor of Science from Allegheny College (1982) and Doctorate of Medicine from The Ohio State University College of Medicine (1987). He completed his internship and residency in Pediatrics at Rainbow Babies & Children's Hospital in 1990, and his fellowship training in the Pediatric Oncology Branch of the National Cancer Institute (NCI) in 1993, in Bethesda, Maryland. John became a tenured investigator and led the NCI's Laboratory of Immunoregulation, where his research focused on basic cancer biology and immunology. Since relocating his laboratory to Cleveland, his research has been funded by several NIH Institutes including the NCI, NHLBI and NEI, and by the Department of Defense. John was recognized as a recipient of the Scholar-Innovator Award of the Harrington Discovery Institute (2017), and he is the scientific co-founder of Modularix and Celloram, two preclinical stage companies devoted to the development of therapeutics for cancer and immune disorders.

John Letterio, MD
Professor of Pediatrics University Hospitals Cleveland, Division Chief,
Pediatric Hematology & Oncology, UH Rainbow Babies & Children's Hospital

Amy LeBlanc is board-certified veterinary oncologist and the Director of the intramural National Cancer Institute's Comparative Oncology Program. In this position she conducts preclinical mouse and translational canine studies that are designed to inform the drug and imaging agent development path for human cancer patients. She also advises leading pharmaceutical companies as well as NCTI’s Division of Cancer Treatment and Diagnosis on the inclusion of pet dogs with cancer into the development path of novel approaches for a variety of malignancies, including immunotherapeutics, targeted small molecules, oncolytic viruses, and cancer imaging agents. She directly oversees the NCI Comparative Oncology Trials Consortium (COTC), which provides infrastructure necessary to connect participating veterinary academic institutions with stakeholders in drug development to execute fit-for-purpose comparative clinical trials in novel therapeutics and imaging agents.

What Do You Hope For:
“My hope is that this meeting of experts from multiple disciplines will further our understanding of this terrible disease and thus its eventual cure.”

Mark Keiran, MD, PhD
Bristol-Myers Squibb

Dr. Kieran is currently the Pediatric Clinical Trial Lead in Oncology Clinical Development, Bristol-Myers Squibb. He received a PhD in Immunology in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. After a post-doctoral fellowship in the Department of Molecular Biology at the Pasteur Institute in Paris, France where he cloned the regulatory molecule NFkB, he completed a pediatric residency at McGill University in Montreal and a pediatric oncology fellowship at Boston Children's Hospital. Dr. Kieran was named Director of Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute in 1998 until his move to BMS in 2018. While in Boston, he developed a large number of first in pediatric clinical trials in the areas of targeted therapeutics, gene therapy, anti-angiogenic modalities and immunotherapy. His ongoing interests include the genomic identification of mutations and incorporation of targeted, biologic, immune and gene therapy for children with cancer.

What Do You Hope For:
“In the future I hope to cure more of the osteosarcoma patients I take care of and, as a result, know even more OsteoWarriors who are living healthy and fulfilling lives after treatment.”
Dr. Livingston is Assistant Professor in the Department of Sarcoma Medical Oncology and Department of Pediatrics at the University of Texas MD Anderson Cancer Center where he serves as the Co-leader for the MDACC Adolescent and Young Adult Program. He completed combined training in internal medicine and pediatrics at Duke University prior to fellowship training in hematology and medical oncology at MD Anderson Cancer Center. During his fellowship, he conducted lab-based translational research under the mentorship of Dr. Genie Kleinerman which has fueled his interest in osteosarcoma. Despite the existence of high genomic complexity, immune checkpoint inhibitors have shown limited clinical activity in patients with relapsed or metastatic osteosarcoma. Dr. Livingston’s current research is focused on understanding primary immune and genomic mechanisms of resistance to immunotherapy in OS and devising novel immunotherapy approaches for patients with relapsed/metastatic disease.

What Do You Hope For:
“I am excited to attend my first FACTOR conference – to share my work, develop new collaborations and be inspired by the many osteosarcoma MIB Agents.”

Robbie Majzner is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. Dr. Majzner attended Harvard Medical School, where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he cared for some of the first pediatric patients to receive CD19 chimeric antigen receptor (CAR) T cells, children with B cell acute lymphoblastic leukemia (B-ALL) who often had no other therapeutic option. Witnessing the success of CAR T cells in these patients drove him to the laboratory, where he focuses on extending the use of CAR T cells to solid tumors. He has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2 B7-H3, and ALK. Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting. By drawing on state of the art bioengineering techniques, the Majzner Laboratory focuses on enhancing the potency and specificity of CAR T cells for children with cancer. Clinically, Dr. Majzner cares for all patients with neuroblastoma at the Lucile Packard Children's Hospital and has a specific interest in bringing novel immunotherapies to clinical trials for these patients and those with other solid tumors.

What Do You Hope For:
“A cure for osteosarcoma without toxicity.”

Corrie Painter is the associate director of operations and scientific outreach in the Cancer Program of the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, Painter serves as the associate director of Count Me In, which launches patient-driven research projects across multiple cancer types. In this role, she partners with advocacy groups and engages patients with metastatic breast cancer, angiosarcoma, and other cancers through social media in order to carry patient-driven genomic initiatives where patients can consent online to donate their stored tumor samples, saliva samples, medical records, and their voices in order to directly accelerate the pace of discovery. These efforts can be followed on Twitter @Corrie_Painter, and on Facebook, the Metastatic Breast Cancer Project and the Angiosarcoma Project Working Group. Prior to joining the Broad Institute in 2015, Painter was vice president and co-founder of Angiosarcoma Awareness Inc., a nonprofit devoted to fostering a collaborative atmosphere between researchers in order to generate data and reagents that can be shared by the sarcoma community as a whole. She continues in this role alongside her work at the Broad Institute. Painter obtained her Ph.D. in biochemistry from the University of Massachusetts Medical School and completed her postdoc in cancer immunology at UMass Medical School's Cancer Research Institute.
Janet Panoch
Indiana University, PhD Candidate
Amputee Coalition, Resource Development Manager

Janet Panoch is completing a PhD in Health Communication at Indiana University in early 2020. She divides her time between Indianapolis and Washington, DC where she works at the Resource Development Manager for the Amputee Coalition. Janet's journey in pediatric oncology began with her daughter’s diagnosis of osteosarcoma in 2007 and subsequent above knee amputation in 2018. Janet's special interests include qualitative research analysis, patient advocacy, and shared decision making between patients, parents, and providers. Janet has three adult children and three grandsons in Indiana and embraces every opportunity for fossil hunting, kayaking, and tree hugging.

Best Thing About The FACTOR Conference:
“As a parent, the most meaningful part of attending MIB FACTOR conferences is connecting with other families affected by osteosarcoma. As a health communication researcher, the opportunity to hear about cutting edge research specific to osteosarcoma has been invaluable.”

Lauren Ramer
MIB Agents Junior Board Member
Multiple Cancer Survivor

Lauren was diagnosed with extraskeletal osteosarcoma in 2017. Her brother was diagnosed with osteosarcoma in 2011 and passed away in 2017 to leukemia. Lauren and her brother have Li-Fraumeni syndrome which is a genetic predisposition to cancer. She bravely shares her story to increase awareness and funding for osteosarcoma research. MIB Agents is honored to have Lauren speaking at FACTOR 2020.

Best Thing About The FACTOR Conference:
“One of the most impactful parts of this whole experience is knowing I’m not alone and there are others that can understand what I have been through.”

What Do You Hope For:
“I hope that we develop a better way to fight osteosarcoma. I hope to not watch any more of my friends and family experience the emotional and physical hardships of dealing with or watching a loved one fight osteosarcoma.”

Ryan D. Roberts, MD, PhD
Nationwide Children’s Hospital, Division of Hematology and Oncology

Dr. Roberts is a physician for the Division of Hematology and Oncology at Nationwide Children's Hospital, a principal investigator for the Center for Childhood Cancer and Blood Diseases at The Research Institute at Nationwide Children's Hospital and a member of the Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University. Dr. Roberts is a graduate of the Medical Scientist Training Program at the Ohio State University and of the Pediatrics Residency and Pediatric Hematology, Oncology, and BMT Fellowship at Nationwide Children's Hospital. In 2016, he joined the faculty of the Research Institute at Nationwide Children's hospital, building on the research program that he developed as a resident and fellow.

Peter Scacheri, PhD
Professor, Department of Genetics and Genome Sciences, School of Medicine, Case Western Reserve University

Dr. Peter Scacheri holds the Gertrude and Donnelly Hess Professorship in Oncology and is a tenured Professor in the Department of Genetics and Genome Sciences at Case Western Reserve School of Medicine. He is also a member of the Case Comprehensive Cancer Center. Dr. Scacheri's research focuses on mechanisms that switch on genes that drive the formation cancer and its progression to overt metastasis. Dr. Scacheri has published more than 75 peer reviewed papers as well as numerous book chapters, reviews and perspective articles. He is a standing member on the NIH Cancer Genetics study section, serves on several Editorial Boards, and has led the American Society of Human Genetics Scientific Program Committee. Dr. Scacheri is also deeply committed to graduate student training. Since establishing his lab in 2006, seven trainees have earned their doctorate degrees under his mentorship. Dr. Scacheri's research program is supported by multiple grants from the National Institutes of Health, as well as several foundations and gifts from generous donors.
Dr. Joshua Schiffman is a pediatric oncologist at the University of Utah, where he is a Professor of Pediatrics and an Adjunct Professor of Oncological Sciences. Dr. Schiffman works as an Investigator at Huntsman Cancer Institute (HCI) and his laboratory explores the translation of cancer genomics and evolutionary medicine into patient care. Dr. Schiffman serves as the Medical Director for the Family Cancer Assessment Clinic at HCI where he oversees the care of children and families with high genetic risk for cancer. Dr. Schiffman’s research is particularly focused on sarcomas that impact children, like osteosarcoma. Dr. Schiffman is also the CEO and Co-Founder of PEEL Therapeutics, delivering evolution-inspired medicine to patients. In addition, Dr. Schiffman co-founded ItRunsInMyFamily.com, an online family history collection tool to help identify those at highest risk for developing cancer. Dr. Schiffman graduated from Brown University School of Medicine in 2000, followed by clinical training in Pediatrics and Pediatric Hematology-Oncology at Stanford University from 2000-2008. His academic research and now commercial efforts focus on genomic development of cancer in children and studying animals that naturally are protected from cancer, like elephants. Dr. Schiffman has co-founded several exciting new startup companies to impact osteosarcoma diagnosis, treatment, and prevention.

Dr. Bryan Sisk is a communication researcher and clinical fellow in pediatric hematology and oncology at Washington University in St. Louis. Dr. Sisk’s research focuses on understanding how communication functions in pediatric oncology, and identifying personal and systems-level barriers to communicating effectively. He has published more than 40 papers in high-impact journals focused on communication research, normative ethics, and personal narrative, and he has authored 3 book chapters on ethics and communication. He is also the author of the book, A Lasting Effect: Reflections on Music and Medicine, which recounts his experiences with seriously ill children as a volunteer musician in a pediatric hospital. In the future, Dr. Sisk aims to develop communication interventions that will improve the care provided to all children with cancer and their families. Dr. Sisk lives in St. Louis, MO with his wife and three young children.

What Do You Hope For:
“In the future, I hope that all children with cancer and their families become more fully engaged in meaningful communication that improves their social, psychological, and medical outcomes.”

Best Thing About The FACTOR Conference:
“The opportunity to interact with both other oncologists and patient advocates.”

Dr. Matteo Trucco received his training in Pediatric Hematology/Oncology from Johns Hopkins University and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies. As the Director of the Pediatric Phase 1 Program at the University of Miami-Sylvester Comprehensive Cancer Center he seeks to identify novel approaches to treating Pediatric Sarcomas, with a particular interest in targeting sarcomas’ metabolism, their hypoxic areas and sarcoma stem cells. He jumped at the opportunity to help bring together researchers, clinicians, patients and advocates as part of the FACTOR conference to stimulate innovation and collaboration to advance the research and treatment of Osteosarcoma.
Christine Zwick, DPT
Physical Therapist
Nemours – Al duPont Hospital for Children

Christine received her Doctorate of Physical Therapy from the University of Delaware. She is a senior pediatric physical therapist at AI duPont Hospital for Children and has been practicing as a physical therapist for 12 years. She is the lead physical therapist working with patients from the oncology department. Christine has been an active research data collector for the Childrens Oncology Group since 2011.

What Do You Hope For:
“I hope for a future where the lasting effects of cancer treatment are minimized so children can resume active lifestyles within their community after treatment.”

Jason Yustein, MD, PhD
Associate Professor
Texas Children’s Cancer Center
Baylor College of Medicine

As a pediatric oncologist and physician-scientist with significant training in molecular and cellular biology I have been fortunate enough to design and merge my laboratory research and clinical interests. I recognize the need for improving our understanding of the molecular pathogenesis of sarcomas and the identification of new therapeutic avenues, especially for patients with therapeutic resistant and/or metastatic disease. My laboratory has tremendous interest and experience in merging innovative murine models and patient-derived resources towards garnering molecular insights into sarcoma initiation, development/resistance and metastatic progression and translating these findings towards testing novel therapeutic interventions for these aggressive malignancies.

What Do You Hope For:
“I hope for an engaging and interactive meeting with active discussions on the present limitations as well as areas for advancing current and developing new avenues for studying and treating osteosarcoma. I look forward to seeing old colleagues, and hope to meet other investigators and develop new potential areas for collaboration.”

Vuja De MIB Conference Ad.indd   1/5/20   8:18 PM

THE OSTEOSARCOMA COLLABORATIVE
Working Together To Find A Cure

Identifying & Developing New Osteosarcoma Therapeutics Uniquely Suited to Prevent Metastasis and Recurrence

What Do You Hope For:
“Some small steps forward in the fight against osteosarcoma – en route to the giant leap!”
– Prof. Stefan Bielack, MD

“I think that everything we do has a common goal: to be happy. Happiness to me, is being able to look back at the end of my day, week, year, life and feel like I contributed to making this World a better place. So I hope that at the end of every day, week, year, and particularly at the end of my life, I can look back and know that I did everything in my power to help advance science so that one day, every child can hope to reach happiness.”
– Claudia A. Benavente, PhD

“I hope to have the opportunity to interact with and learn from individuals touched by cancer, with the goal of improving future experiences for patients, families, and providers alike.”
– Kate E. Eshleman, PsyD

“I hope for improved outcomes for both human and canine osteosarcoma patients through our collaborative efforts in comparative oncology.”
– Amy LeBlanc, DVM
WITH HEARTFELT APPRECIATION

THE JEFFRIES FAMILY
The Jeffries Family contributes greatly to MIB Agents all year long and to the FACTOR Conference annually. Gigi serves on MIB Agents Board of Directors, has been the OsteoWarriors HQ Chief for three years, and a consultant this fourth year. Because of Gigi and the entire Jeffries Family, the OsteoWarriors Headquarters (HQ) continues to create joy, connection and belonging for our warriors.

THE SEGAL FAMILY
Dr. & Mrs. Scott Segal's support of MIB Agents and the FACTOR conference since the beginning has been so meaningful. They are a part of our annual OutSmarting Osteosarcoma Research and contribute impact-fully to important work in pediatric cancer as a whole. They are responsible for the complete and utter spoiling of our speakers every year, with a delicious dinner and gracious hospitality at each FACTOR conference.

THE VAN SCOTT FAMILY
There are Secret Special Agents among us, and they are the Van Scotts. They Make It Better literally every single day for MIB Agents and the missions we undertake. We have the confidence to move forward with various initiatives, great and small because of their support. How incredibly grateful we are to them for their trust, friendship, and support in our mission to Make It Better.

OSTEOSARCOMA INSTITUTE
We are truly grateful for the Osteosarcoma Institute and their brilliant, focused and dedicated team's commitment to osteosarcoma patients, physicians and researchers. More than their wholehearted and generous support of FACTOR, we are grateful for their ongoing partnership in making it better for all osteosarcoma constituents. How honored we are to work together with this team!

COMMANDER MOHAN ANAND
Mohan passed from osteosarcoma after a battle he silently fought while Project Manager for the first FACTOR Conference in 2017. He made sure that the conference was funded and a “go”. He is a part of every conference - in this program and honored by our signature “Mohanito” Cocktail at the Welcome Reception. He enjoyed our first Welcome Reception via FaceTime in 2017 from his hospital bed and passed a few days after FACTOR 2017. He is greatly missed by MIB Agents, his family, and friends.

FACTOR TEAM
The pursuit of any goal desires the hearts of many. The FACTOR Team has committed their varied and excellent talents and a lot of time to bring this conference to fruition. They are the doers. Thank you Team!

Ann Graham, Co-Chair
FACTOR Founder
MIB Agents Founder
President, Board of Directors

Matteo Trucco, MD, Co-Chair
Director, Children's Cancer Innovative Therapy Program
Associate Staff | Peds Hematology-Oncology & BMT
MIB Agents Board of Directors
Scientific Advisory Team
Editor: Osteosarcoma: From Our Family to Yours

Mary O'Hannigan
MIB Agents FACTOR HQ Coordinator

Briana Paronto
MIB Agents’ Marketing and Donor Relations Chief
FACTOR Administrative Assistant

Casey Crossan
MIB Agents OsteoAngel Coordinator
Speaker Chief
MIB Agents Development and Operations Chief

Liz Vallejo
Volunteer Coordinator, Floor Chief
MIB Programs Chief
Author: Osteosarcoma: From Our Family to Yours

John Graham
MIB Agents VP Board of Directors,
MIB Agents OutRunning Osteosarcoma Team

Sarah Goobic
MIB Agents Registration Agent

Linda Kennington
MIB Agents Photographer

Vanessa Valenti
MIB Agents OutRunning Osteosarcoma Coordinator

Maureen Smart
MIB Ambassador Agent Training Chief

Tedd Kapinos and Mark Atkins
MIB Agents who make it all beautifully better

Slaven Gujic
MIB Agents videography team

Rebecca Rogers, Alexis Johnson, Sloane Dyer,
Annika Vallejo, Molly O'Hannigan, Valarie Schull,
Erika Matich, Tim Brosnan, Joe O'Hannigan,
Mark O'Hannigan, Sean Brosnan, Christiane Robbins,
Amy Brosnan, Joe Cristo, Cheryl Putnam
and MIB Agent Volunteers Everywhere!
MIB AGENTS BOARD MEMBERS

Ann Graham
President & Founder, MIB Board of Directors

John Graham
VP, MIB Agents Board of Directors
Managing Partner, Twin Farms

Susan Altamore Carusi, Esq
Secretary of the Board of Directors

Mary Kedzie, CPA
Treasurer of the Board of Directors

Nina Pickett
Board Member, MIB Agents
Senior Director, Pediatrics, Memorial Sloan Kettering Cancer Center

Laura Faught
Board Member, MIB Agents
COO Ansley Communications

Gigi Jeffries, PhD
Board Member, MIB Agents

Matteo Trucco, MD
Board Member, MIB Agents
Cleveland Clinic
Pediatric Hematology Oncology and Blood and Marrow Transplantation
Director Children’s Cancer Innovative Therapy Program

Katie Lembo
Board Member, MIB Agents
Nordic Business & Cross-Functional Team Leader, Hematology at Janssen Pharmaceutical

Pete Anderson, MD, PhD
Board Member, MIB Agents
Cleveland Clinic
Pediatric Hematology Oncology and Blood and Marrow Transplantation

John H. Healey, MD, FACS
Board Member, MIB Agents
Memorial Sloan Kettering Cancer Center
Chief, Orthopaedic Service; Stephen McDermott Chair in Surgery
MIB AGENTS
JUNIOR BOARD MEMBERS

Pete Anderson, MD PhD
Cleveland Clinic
Pediatric Hematology Oncology and Blood and Marrow Transplantation

John H. Healey, MD, FACS
Memorial Sloan Kettering Cancer Center
Chief, Orthopaedic Service; Stephen McDermott Chair in Surgery

Matteo Trucco, MD
Cleveland Clinic
Pediatric Hematology Oncology, Blood & Marrow Transplantation Director Children’s Cancer Innovative Therapy Program

Ramy Ibrahim, MD
Parker Institute
Chief Medical Officer and Vice President, Clinical Development

Rosandra Kaplan, MD
National Cancer Institute Investigator
Pediatric Oncology Branch Head, Tumor Microenvironment Section

MIB AGENTS
SCIENTIFIC ADVISORY TEAM

Damon Reed, MD
Moffitt Cancer Center
Program Leader, Adolescent Young Adult Program

John H. Healey, MD, FACS
Memorial Sloan Kettering Cancer Center
Chief, Orthopaedic Service; Stephen McDermott Chair in Surgery

Pete Anderson, MD PhD
Cleveland Clinic
Pediatric Hematology Oncology and Blood and Marrow Transplantation
Extraordinary cancer care.
For extraordinary kids of all ages.

Zoryah and her sister, Zoie, an MSK Kids family

“Faith is to believe what you do not see; the reward of this faith is to see what you believe.”
– St. Augustine
#BelieveInBetter
#MakeItBetter
#Osteosarcoma